Combined Tyrosine and Serine/Threonine Kinase Inhibition by Sorafenib Prevents Progression of Experimental Pulmonary Hypertension and Myocardial Remodeling

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Circulation

• Publication date

  2008-11-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/CIRCULATIONAHA.108.779751PMID 18955668
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Discovery and development of sorafenib: a multikinase inhibitor for treating cancer

  2007cited by this paper
• Cardiotoxicity of imatinib mesylate: an extremely rare phenomenon or a major side effect?

  2007cited by this paper
• Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

  2007cited by this paper
• Endothelin-1, but not Ang II, Activates MAP Kinases Through c-Src–Independent Ras-Raf–Dependent Pathways in Vascular Smooth Muscle Cells

  2007cited by this paper
• Fibroblast Growth Factor-2 Expression Is Altered in Lambs With Increased Pulmonary Blood Flow and Pulmonary Hypertension

  2007cited by this paper
• Vasopressin promotes cardiomyocyte hypertrophy via the vasopressin V1A receptor in neonatal mice.

  2007cited by this paper
• ASCO 2006 highlights: targeted therapy for renal cell carcinoma.

  2007cited by this paper
• VEGF‐R blockade causes endothelial cell apoptosis, expansion of surviving CD34+ precursor cells and transdifferentiation to smooth muscle‐like and neuronal‐like cells

  2007cited by this paper
• Protein Kinase C Regulates Internal Initiation of Translation of the GATA-4 mRNA following Vasopressin-induced Hypertrophy of Cardiac Myocytes*

  2007cited by this paper
• Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension

  2007cited by this paper
• Discovery and development of sorafenib: a multikinase inhibitor for treating cancer

  2006cited by this paper
• Antioxidant actions contribute to the antihypertrophic effects of atrial natriuretic peptide in neonatal rat cardiomyocytes.

  2006cited by this paper
• Long term imatinib treatment in pulmonary arterial hypertension.

  2006cited by this paper
• Vascular endothelial growth factor in the lung.

  2006cited by this paper
• Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension.

  2006cited by this paper
• Cardiotoxicity of the cancer therapeutic agent imatinib mesylate

  2006cited by this paper
• TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling.

  2006cited by this paper
• Comparing the global mRNA expression profile of human atrial and ventricular myocardium with high-density oligonucleotide arrays.

  2005cited by this paper
• Increased Cardiac Expression of Tissue Inhibitor of Metalloproteinase-1 and Tissue Inhibitor of Metalloproteinase-2 Is Related to Cardiac Fibrosis and Dysfunction in the Chronic Pressure-Overloaded Human Heart

  2005cited by this paper
• Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension.

  2005cited by this paper
• Epidermal Growth Factor Receptor Blockade Mediates Smooth Muscle Cell Apoptosis and Improves Survival in Rats With Pulmonary Hypertension

  2005cited by this paper
• Lessons learned from cancer may help in the treatment of pulmonary hypertension.

  2005cited by this paper
• Reversal of experimental pulmonary hypertension by PDGF inhibition.

  2005cited by this paper
• Imatinib for the treatment of pulmonary arterial hypertension.

  2005cited by this paper
• BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

  2004cited by this paper
• Raf-1 Kinase Is Required for Cardiac Hypertrophy and Cardiomyocyte Survival in Response to Pressure Overload

  2004cited by this paper
• Lung-targeted VEGF inactivation leads to an emphysema phenotype in mice.

  2004cited by this paper
• Cellular and molecular pathobiology of pulmonary arterial hypertension.

  2004cited by this paper
• Ras, Akt, and Mechanotransduction in the Cardiac Myocyte

  2003cited by this paper
• A bradykinin antagonist and a caspase inhibitor prevent severe pulmonary hypertension in a rat model.

  2002cited by this paper
• Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

  2002cited by this paper
• Gene Expression Patterns in the Lungs of Patients With Primary Pulmonary Hypertension: A Gene Microarray Analysis

  2001cited by this paper
• Vasopressin-induced hypertrophy in H9c2 heart-derived myocytes.

  2000cited by this paper
• Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V(1A) receptor.

  2000cited by this paper
• Inhibition of VEGF receptors causes lung cell apoptosis and emphysema.

  2000cited by this paper
• Organization and regulation of mitogen-activated protein kinase signaling pathways.

  1999cited by this paper
• Primary pulmonary hypertension between inflammation and cancer.

  1998cited by this paper
• Increased vascular endothelial growth factor production in the lungs of rats with hypoxia-induced pulmonary hypertension.

  1998cited by this paper
• Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients.

  1998cited by this paper
• Tenascin-C, proliferation and subendothelial fibronectin in progressive pulmonary vascular disease.

  1997cited by this paper

• A Proteomics Resource Investigating Fibrosis: Proof‐of‐Concept for Identifying Novel Drug Candidates

  2025cites this paper
• Tyrosine Kinase Inhibitors for Treatment of Pulmonary Arterial Hypertension

  2025cites this paper
• Searching for Old and New Small-Molecule Protein Kinase Inhibitors as Effective Treatments in Pulmonary Hypertension—A Systematic Review

  2024cites this paper
• Pulmonary Hypertension and Right Ventricle: A Pathophysiological Insight

  2024cites this paper
• Nebulisation of Paclitaxel, Sotatercept and Iloprost for pulmonary hypertension for lung cancer. From In vitro to In vivo

  2024cites this paper
• Cardiopulmonary bypass activates classical monocytes via shear-mediated activation of Store-Operated Calcium Entry

  2024cites this paper
• Inhaled nintentanib, pirfenidone and macitentan for pulmonary fibrosis: a laboratory experiment.

  2023cites this paper
• Pathophysiology and new advances in pulmonary hypertension

  2023cites this paper
• Pathophysiological Involvement of Mast Cells and the Lipid Mediators in Pulmonary Vascular Remodeling

  2023cites this paper
• New Drugs and Therapies in Pulmonary Arterial Hypertension

  2023cites this paper
• Landscape of molecular crosstalk between SARS-CoV-2 infection and cardiovascular diseases: emphasis on mitochondrial dysfunction and immune-inflammation

  2023cites this paper
• NEW OPPORTUNITIES PATHOGENETIC THERAPY OF PULMONARY ARTERIAL HYPERTENSION

  2022cites this paper
• The Pathobiology of Pulmonary Arterial Hypertension.

  2022cites this paper
• Inhibition of KIR2.1 decreases pulmonary artery smooth muscle cell proliferation and migration

  2022cites this paper
• Melatonin activates the Mst1-Nrf2 signaling to alleviate cardiac hypertrophy in pulmonary arterial hypertension.

  2022cites this paper
• The Platelet-Derived Growth Factor Pathway in Pulmonary Arterial Hypertension: Still an Interesting Target?

  2022cites this paper
• Reversal of pulmonary arterial hypertension and neointimal formation by kinin B1 receptor blockade

  2021cites this paper
• Inflammatory Mechanisms in the Pathogenesis of Pulmonary Arterial Hypertension: Recent Advances.

  2021cites this paper
• mTOR Signaling in Pulmonary Vascular Disease: Pathogenic Role and Therapeutic Target

  2021influential citation
• Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial

  2021cites this paper
• Therapeutic Potential of Regorafenib—A Multikinase Inhibitor in Pulmonary Hypertension

  2021cites this paper
• Novel Experimental Therapies for Treatment of Pulmonary Arterial Hypertension

  2021cites this paper
• Pulmonary arterial hypertension specific therapy: The old and the new.

  2020cites this paper
• A novel rat model of pulmonary hypertension induced by mono treatment with SU5416

  2020cites this paper
• Phenotype and Outcomes of Pulmonary Hypertension Associated with Neurofibromatosis Type 1.

  2020cites this paper
• Beyond Thrombosis: the Role of Platelets in Pulmonary Hypertension

  2020cites this paper
• Tyrosine kinase inhibitors relax pulmonary arteries in human and murine precision-cut lung slices

  2019cites this paper
• Inhibition of Shp2 ameliorates monocrotaline-induced pulmonary arterial hypertension in rats

  2018cites this paper
• Reversal effects of low-dose imatinib compared with sunitinib on monocrotaline-induced pulmonary and right ventricular remodeling in rats.

  2018cites this paper
• Effects of toceranib compared with sorafenib on monocrotaline-induced pulmonary arterial hypertension and cardiopulmonary remodeling in rats.

  2018cites this paper
• Therapeutic effect of sorafenib in monocrotaline-induced pulmonary arterial hypertension rats

  2018cites this paper
• Translational Advances in the Field of Pulmonary Hypertension. From Cancer Biology to New Pulmonary Arterial Hypertension Therapeutics. Targeting Cell Growth and Proliferation Signaling Hubs.

  2017cites this paper
• Advances in treatment of pulmonary arterial hypertension: patent review

  2017cites this paper
• Response to the article "Sorafenib as a potential strategy for refractory pulmonary arterial hypertension".

  2017cites this paper
• Autoimmune disease mouse model exhibits pulmonary arterial hypertension

  2017cites this paper
• The cancer theory of pulmonary arterial hypertension

  2017cites this paper
• Sorafenib as a potential strategy for refractory pulmonary arterial hypertension.

  2017cites this paper
• Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives

  2017cites this paper
• PULMONARY PERSPECTIVE

  2017influential citation
• Treatment with platelet-derived growth factor (PDGF) and rock inhibitors is related to declined nerve growth factor (NGF) signaling in an experimental model of rat pulmonary hypertension

  2017cites this paper
• Title: TREATMENT WITH PLATELET-DERIVED GROWTH FACTOR (PDGF) AND ROCK INHIBITORS IS RELATED TO DECLINED NERVE GROWTH FACTOR (NGF) SIGNALING IN AN EXPERIMENTAL MODEL OF RAT PULMONARY HYPERTENSION

  2017cites this paper
• Steps forward in the treatment of pulmonary arterial hypertension: latest developments and clinical opportunities

  2017cites this paper
• Pulmonary hypertension; aetio-pathogenesis, current treatment and future prospects

  2017cites this paper
• Pulmonary Hypertension and Cancer

  2017cites this paper
• Novel strategies for treatment of pulmonary arterial hypertension.

  2017cites this paper
• Pharmacotherapy for Pulmonary Hypertension: Future Directions

  2017cites this paper
• PDGF‐dependent β‐catenin activation is associated with abnormal pulmonary artery smooth muscle cell proliferation in pulmonary arterial hypertension

  2016cites this paper
• Raf/ERK drives the proliferative and invasive phenotype of BMPR2-silenced pulmonary artery endothelial cells.

  2016cites this paper
• Изучение распределения метронидазола в опухолевой ткани прямой кишки при аппликационном способе введения в эксперименте in vivo

  2016cites this paper
• The Effect of Sorafenib, Tadalafil and Macitentan Treatments on Thyroxin-Induced Hemodynamic Changes and Cardiac Abnormalities

  2016cites this paper
• 4-Phenylbutyric Acid Induces Protection against Pulmonary Arterial Hypertension in Rats

  2016cites this paper
• Sildenafil attenuates hypoxic pulmonary remodelling by inhibiting bone marrow progenitor cells

  2016cites this paper
• In vitro and in vivo activity of a novel sorafenib derivative SC5005 against MRSA.

  2016cites this paper
• Activation of the Na+/H+ exchanger in isolated cardiomyocytes through β-Raf dependent pathways. Role of Thr653 of the cytosolic tail.

  2016cites this paper
• Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.

  2015cites this paper
• Cardiac and vascular toxicities of angiogenesis inhibitors: The other side of the coin.

  2015cites this paper
• HMG-COA reductase inhibitors: An opportunity for the improvement of imatinib safety. An experimental study in rat pulmonary hypertension

  2015influential citation
• Novel therapeutic approaches for pulmonary arterial hypertension: Unique molecular targets to site-specific drug delivery.

  2015cites this paper
• Pathogenesis of Pulmonary Arterial Hypertension

  2015cites this paper
• Influence of imatinib at a low dose and sildenafil on pulmonary hypertension in rats.

  2015cites this paper
• Novel and emerging therapies for pulmonary hypertension.

  2014cites this paper
• Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment

  2014cites this paper
• Multikinase inhibitor sorafenib prevents pressure overload-induced left ventricular hypertrophy in rats by blocking the c-Raf/ERK1/2 signaling pathway

  2014cites this paper
• Concurrent Rho-Kinase and Tyrosine Kinase Platelet-Derived Growth Factor Inhibition in Experimental Pulmonary Hypertension

  2014cites this paper
• Novel Mechanisms of Sildenafil in Pulmonary Hypertension Involving Cytokines/Chemokines, MAP Kinases and Akt

  2014cites this paper
• The metabolic basis of pulmonary arterial hypertension.

  2014cites this paper
• Targeted therapies in pulmonary arterial hypertension.

  2014cites this paper
• The current approach into signaling pathways in pulmonary arterial hypertension and their implication in novel therapeutic strategies

  2014cites this paper
• Vascular Stiffening in Pulmonary Hypertension: Cause or Consequence? (2013 Grover Conference Series)

  2014cites this paper
• L’hypertension pulmonaire : physiopathologie, traitements actuels et perspectives innovantes : exemple du facteur de croissance des nerfs (NGF) comme nouvelle cible potentielle

  2014cites this paper
• Pulmonary Hypertension Associated with Connective Tissue Disease

  2014cites this paper
• Thrombin Has Biphasic Effects on the Nitric Oxide-cGMP Pathway in Endothelial Cells and Contributes to Experimental Pulmonary Hypertension

  2013cites this paper
• Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension

  2013influential citation
• Tyrosine Kinase Inhibitors in Pulmonary Arterial Hypertension: A Double-Edge Sword?

  2013cites this paper
• Prostaglandin I2 induces apoptosis via upregulation of Fas ligand in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension.

  2013cites this paper
• Metabolic Remodeling and Mitochondrial Dysfunction in Maladaptive Right Ventricular Hypertrophy Secondary to Pulmonary Arterial hypertension

  2013cites this paper
• A lymphocyte-dependent mode of action for imatinib mesylate in experimental pulmonary hypertension.

  2013cites this paper
• Mechanics and mechanisms of pulmonary hypertension—Conference summary and translational perspectives

  2013cites this paper
• The emergence of new therapeutic targets in pulmonary arterial hypertension: from now to the near future

  2013cites this paper
• Pediatric pulmonary hypertension.

  2013cites this paper
• CARDIOVASCULAR , PULMONARY , AND RENAL PATHOLOGY A Lymphocyte-Dependent Mode of Action for Imatinib Mesylate in Experimental Pulmonary Hypertension

  2013cites this paper
• Everolimus in Patients with Severe Pulmonary Hypertension: A Safety and Efficacy Pilot Trial

  2013cites this paper
• Smooth muscle cell proliferation and endothelin pathway in pulmonary arterial hypertension : comparative effects of current and putative therapeutic agents

  2013cites this paper
• Therapeutic effect of low-dose imatinib on pulmonary arterial hypertension in dogs.

  2013cites this paper
• Effects of Multikinase inhibitors on pressure overload-induced right ventricular remodelling

  2013cites this paper
• BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I

  2013cites this paper
• The Pharmacological Treatment of Pulmonary Arterial Hypertension

  2012cites this paper
• Immune and inflammatory mechanisms in pulmonary arterial hypertension.

  2012cites this paper
• Hypertension artérielle pulmonaire et inhibiteurs de tyrosine kinase

  2012cites this paper
• The monocrotaline model of pulmonary hypertension in perspective.

  2012cites this paper
• WHO Group 1 pulmonary arterial hypertension: current and investigative therapies.

  2012cites this paper
• Signaling to Cardiac Hypertrophy: Insights from Human and Mouse RASopathies

  2012cites this paper
• Protein Kinases in the Heart: Lessons Learned from Targeted Cancer Therapeutics

  2012cites this paper
• Platelets in Pulmonary Hypertension: a Causative Role or a Simple Association?

  2012cites this paper
• [Pathophysiology of pulmonary hypertension: advances and prospects].

  2012cites this paper
• Tyrosine kinase inhibitor (TKI)‐induced cardiotoxicity: approaches to narrow the gaps between preclinical safety evaluation and clinical outcome

  2012cites this paper
• Current and future treatment of pulmonary hypertension.

  2012cites this paper
• [Non oncologic applications of molecular targeted therapies].

  2012cites this paper
• Translational Vascular Medicine

  2012cites this paper
• Systemic sclerosis-related pulmonary hypertension: unique characteristics and future treatment targets.

  2012cites this paper